F2 and glycogen storage disease VI: Although not standard therapy, because of the severity of the cutaneous microthrombotic disease and recurrent areas of painful erythema with attempts at corticosteroid reduction while on apixaban, rituximab-pvv was added to her regimen leading to normalization of the test for antibodies to phosphatidylserine/prothrombin complex and cessation of cutaneous thrombotic events although low-level elevations of platelets and D-dimer have persisted.